BCM
ACTU

BIOS Capital Management’s Actuate Therapeutics ACTU Stock Holding History

BIOS Capital Management’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.5M Hold
10,049,996
– – 52.09% 1
2025
Q4 		$61.5M Hold
10,049,996
– – 74.44% 1
2025
Q3 		$67.2M Buy
10,049,996
+84,917
+0.9% +$616K 75.62% 1
2025
Q2 		$60.9M Buy
9,965,079
+71,428
+0.7% +$624K 83.89% 1
2025
Q1 		$67M Hold
9,893,651
– – 84.59% 1
2024
Q4 		$78.8M Buy
+9,893,651
New +$80.7M 83.69% 1

Other funds holding ACTU

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BIOS Capital Management's ACTU Position: Q1 2026 in Review

BIOS Capital Management held its Actuate Therapeutics (ACTU) position steady in Q1 2026 at 10,049,996 shares worth $27.5M. The position accounts for 52.09% of the portfolio, ranked #1.

BIOS Capital Management first reported a position in ACTU in Q4 2024 and has held it in 6 quarters since. The position peaked at $78.8M in Q4 2024. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • BIOS Capital Management held 10,049,996 shares of Actuate Therapeutics worth $27.5M as of Q1 2026.
  • BIOS Capital Management left its Actuate Therapeutics share count unchanged in Q1 2026.
  • Actuate Therapeutics made up 52.09% of BIOS Capital Management's portfolio in Q1 2026, its #1 holding.
  • BIOS Capital Management first reported a position in Actuate Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • BIOS Capital Management's Actuate Therapeutics position peaked at $78.8M in Q4 2024.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on BIOS Capital Management's 13F filing for Q1 2026, filed 13 May 2026.